Aurobindo Pharma Ltd. News and Updates

Name: Latest research reports of Aurobindo Pharma Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 5
Author: ICICI Direct

Keep track of all breaking news on Aurobindo Pharma Ltd. from all sources in a single place.

Aurobindo Pharma Ltd.

10 Nov 2025, 12:00AM

1154.80

2.76%

Aurobindo Pharma Ltd.

Buy: Aurobindo Pharma Ltd.

Target

ICICI Direct

Q2FY26- Muted numbers on expected lines Revenues grew ~6% YoY to 8286 crore due to softness in the US (44% of the revenues) which grew 3% to 3638 crore. Europe (30% of the revenues) grew 18% to 2480 crore and ARV (~4% of the revenues) grew 68% to 325 crore. Growth Markets (~10% of the revenues) grew ~9% YoY to 882 crore (including India formulations). APIs de-grew at 17% YoY to 961 crores. EBITDA grew 7% YoY to 1678 crore while EBITDA margins increased 16 bps to 20.3%. EBITDA de-growth was mainly driven by increase in employee expenses....

Aurobindo Pharma Ltd.'s price crossed above 200Day SMA today

Aurobindo Pharma Ltd.

10 Nov 2025, 12:00AM

1154.80

2.76%

Outlook supported by recovery in Injectables, ramp-up of Pen-G and biosimilars

Accumulate: Aurobindo Pharma Ltd.

Target

Deven Choksey

Aurobindo Pharma delivered a steady quarter, with revenue growth driven mainly by formulations, particularly Europe and a stable US base supported by new product launches.

Promoters pledged 0.42% of shares in last quarter. Total pledge stands at 17.50% of promoter holdings

Aurobindo Pharma Ltd.

07 Nov 2025

1154.80

2.76%

Aurobindo Pharma (ARBP IN) Q2FY26 Result Update In...

Buy: Aurobindo Pharma Ltd.

Prabhudas Lilladhar

Aurobindo Pharma Ltd.'s price crossed above 200Day SMA today

Aurobindo Pharma Ltd.

07 Nov 2025

1154.80

2.76%

Steady quarter, growth projects on track

Buy: Aurobindo Pharma Ltd.

Target

ICICI Securities Limited

Aurobindo’s Q2FY26 performance was steady, helped by its Europe (+17.8%) and ARV (68.4%) verticals. US sales, at USD 417mn, beat our expectation; though, gRevlimid sales slipped sequentially.

Number of FII/FPI investors decreased from 728 to 700 in Sep 2025 qtr

Aurobindo Pharma Ltd.

07 Nov 2025

1154.80

2.76%

Result Update:Aurobindo Pharma

Buy: Aurobindo Pharma Ltd.

Target

Axis Direct

We maintain our BUY recommendation on the stock with a TP of Rs 1,345/share.

Number of FII/FPI investors decreased from 728 to 700 in Sep 2025 qtr

Aurobindo Pharma Ltd.

06 Nov 2025

1154.80

2.76%

Stock Market Live Updates 06 November 2025: Stock to buy today: Aurobindo Pharma (1,151) BUY

Business Line

Sensex, Nifty, Share Price LIVE: The short-term outlook is bullish for Aurobindo Pharma. The stock rose above its 200-Day Moving Average, currently at 1,132 this week and is holding well above it. The level of 1,130 will now act as a good support and limit the downside. Moving average crossovers on the daily chart also strengthens the bullish case. Immediate resistance is at 1,165 which can be broken in the coming days. Such a break can take Aurobindo Pharma share price up to 1,270 in the coming weeks.

Aurobindo Pharma Ltd. is trading above all available SMAs

Stock to buy today: Aurobindo Pharma (1,151) BUY

Business Line | 06 Nov 2025

Aurobindo Pharma Ltd.

05 Nov 2025

1154.80

2.76%

Aurobindo Pharma's Q2 FY26 net up 3.8% at 848 crore

Business Line

Total revenue of the Hyderabad-based company grew 6.3 per cent to 8,286 crore against 7,796 crore in the year-ago period

Promoters pledged 0.42% of shares in last quarter. Total pledge stands at 17.50% of promoter holdings

Aurobindo Pharma Ltd.

18 Oct 2025

1154.80

2.76%

F&O Strategy: Buy Aurobindo Pharma call

Business Line

A conclusive close above 1,350 will trigger a fresh rally in Aurobindo Pharma that can lift it to fresh heights

Number of FII/FPI investors decreased from 728 to 700 in Sep 2025 qtr

Aurobindo Pharma Ltd.

09 Oct 2025, 06:25PM

1154.80

2.76%

Pharma stocks rise as US considers exempting generics from tariffs

Business Standard

Among major gainers, Aurobindo Pharma led the rally, surging 4.49 per cent to Rs 1,118.9, followed by Lupin, which climbed 2.73 per cent to Rs 1,957.6